Fourth Quarter Operational Highlights and Recent Developments:
Financial Results of Operations for the Three Months Ended December 31, 2012Net revenues increased $1.2 million, or 33%, to $4.9 million for the three-month period ended December 31, 2012, from $3.7 million for the three-month period ended December 31, 2011, as a result of increasing awareness and acceptance of KRYSTEXXA among our target customer base, and to a lesser extent, the impact of our price increases. Over the past year, we have increased the selling price of KRYSTEXXA by approximately 29% from the original list price of $2,300 per vial to $2,962 per vial. We further increased the selling price in 2013 by
|SOURCE Savient Pharmaceuticals, Inc.|
Copyright©2012 PR Newswire.
All rights reserved